

<https://doi.org/10.48047/AFJBS.6.10.2024.3580-3598>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

BIO-FABRICATED TISSUE SCAFFOLDS WITH DRUG-LOADED MICROCHANNELS: ENGINEERING FUNCTIONALIZED CONSTRUCTS FOR REGENERATIVE MEDICINE

Sazedur Rahman Akanda ¹, Payel Pramanick ², Ashok Kumar ³, Suraj Koranga ⁴, Kashmiri sonowal ⁵, Prasanta Deka ⁶, Sandeep Prabhu Gadhwe ⁷, Amit Kumar ^{8*}

1. Research Scholar , School of Pharmaceutical Science, USTM
2. Assistant Professor , Acharya & BM Reddy College of Pharmacy , Soladevanahalli, Hesaraghatta Main Road, Achit Nagar Post, Bengaluru-560107, Karnataka
3. Assistant Professor, School of Pharmaceutical Sciences, Jigyasa University, (Formerly Himgiri Zee University), Sherpur, Chakrata Road, Dehradun, Uttarakhand -248197
4. Assistant Professor, Devsthal Vidyapeeth College of Pharmacy, Lalpur Rudrapur, Uttarakhand
5. Assistant professor, School of Pharmacy, The Assam Kaziranga University, Jorhat, 785006
6. Assistant professor , School of pharmaceutical sciences, University of science and technology Meghalaya, Technocity, Kiling Road, Baridua, 9th mile, Meghalaya 793101
7. Assistant Professor, STES Sinhgad College of Pharmacy, Vadgaon (Bk), Pune-411041
8. Assistant Professor, Shri Ram College of pharmacy, Ramba Karnal Haryana

Corresponding Author: Amit Kumar

Article History

Volume 6, Issue 10, 2024

Received: 20 Apr 2024

Accepted : 10 May 2024

doi: 10.33472/AFJBS.6.10.2024. 3580-3598

Abstract:

Biofabricated tissue scaffolds incorporating drug-loaded microchannels represent a promising advancement in regenerative medicine. These constructs aim to address the limitations of conventional tissue engineering approaches by integrating therapeutic functionalities within the scaffold matrix. The incorporation of microchannels enables precise control over the spatial and temporal release of therapeutic agents, enhancing local tissue regeneration while minimizing systemic side effects. Key considerations in the design include material biocompatibility, mechanical properties, and the bioactive properties of the loaded drugs. Recent developments have focused on optimizing fabrication techniques such as 3D bioprinting and microfluidics to achieve reproducible and customizable scaffold architectures. This review explores the current state-of-the-art in biofabricated tissue scaffolds with drug-loaded microchannels, highlighting their potential applications in diverse clinical scenarios including wound healing, bone regeneration, and organ repair. Future directions involve further refinement of scaffold design, comprehensive preclinical evaluation, and translation to clinical settings to realize their full therapeutic potential in regenerative medicine.

Keywords: tissue engineering, scaffolds, microchannels, drug delivery, regenerative medicine, biofabrication, 3D bioprinting, controlled release, biomaterials.

Introduction

Regenerative medicine represents a transformative approach in medical science aimed at repairing, replacing, or regenerating human cells, tissues, or organs to restore or establish normal function[1]. This field intersects various disciplines, including biology, chemistry, engineering, and medicine, with the ultimate goal of harnessing the body's own repair mechanisms to heal tissues or organs damaged by injury, disease, or aging[2]. Regenerative medicine encompasses several key strategies: stem cell therapy, tissue engineering, and the use of biomaterials and growth factors to foster tissue regeneration. Stem cell therapy involves the use of undifferentiated cells that can proliferate and differentiate into specialized cell types. Tissue engineering combines scaffolds, cells, and biologically active molecules to create functional tissues[3,4]. Biomaterials, either synthetic or natural, provide the structural framework necessary for cell attachment and tissue formation. The significance of regenerative medicine lies in its potential to address the limitations of conventional treatments. Traditional approaches often involve symptomatic relief or the use of synthetic implants, which may not integrate well with the body's tissues and can lead to complications such as rejection or infection[5]. In contrast, regenerative medicine aims to restore the native tissue's structure and function, offering more permanent and effective solutions. Tissue scaffolds are critical components in the field of regenerative medicine[6]. These structures provide a three-

dimensional framework that supports cell attachment, proliferation, and differentiation. Scaffolds mimic the extracellular matrix (ECM), the natural environment of cells, providing mechanical support and biological cues essential for tissue formation. Scaffolds must meet several criteria to be effective in tissue regeneration[7]. They should be biocompatible, allowing cells to attach and proliferate without eliciting an adverse immune response. Biodegradability is another key factor; scaffolds should degrade at a rate that matches tissue formation, ensuring that they do not interfere with the developing tissue[8]. Additionally, scaffolds should have suitable mechanical properties to support the specific tissue type being regenerated and possess an interconnected porous structure to facilitate nutrient and waste exchange[9]. Tissue scaffolds can be fabricated from a variety of materials, including natural polymers (e.g., collagen, hyaluronic acid), synthetic polymers (e.g., polylactic acid, polyglycolic acid), and composite materials. Advanced fabrication techniques, such as 3D bioprinting and electrospinning, allow for precise control over scaffold architecture, enabling the creation of complex structures that closely mimic natural tissues[10].

Purpose of Discussing Biofabricated Tissue Scaffolds with Drug-Loaded Microchannels

The primary aim of this review is to explore the emerging field of biofabricated tissue scaffolds with drug-loaded microchannels and their potential applications in regenerative medicine. Biofabrication involves the use of advanced manufacturing technologies to create complex, biologically functional scaffolds[11]. These scaffolds are designed not only to provide structural support but also to deliver therapeutic agents directly to the site of tissue regeneration. Drug-loaded microchannels within scaffolds offer a unique approach to enhance tissue regeneration. These microchannels can be engineered to contain and release drugs, growth factors, or other bioactive molecules in a controlled manner[12]. This localized delivery system ensures that the therapeutic agents are concentrated at the target site, reducing the risk of systemic side effects and improving the efficacy of treatment. The integration of drug delivery systems within scaffolds addresses several challenges in regenerative medicine[13]. For example, it can enhance the scaffold's bioactivity, promote angiogenesis (the formation of new blood vessels), and modulate the immune response to support tissue healing. Additionally, controlled release mechanisms can provide sustained delivery of therapeutics over time, matching the dynamic needs of the regenerating tissue[14].

Tissue Engineering and Regenerative Medicine

Tissue engineering is a multidisciplinary field that combines principles from engineering, biology, and material science to develop biological substitutes that restore, maintain, or improve tissue function. It involves creating scaffolds, which are three-dimensional structures that support cell growth and tissue formation. These scaffolds can be seeded with cells and biochemically stimulated to grow and develop into functional tissues[15].

Historical Development and Milestones

The field of tissue engineering has a rich history marked by significant milestones. In the early foundations of the 1960s-1970s, skin grafting emerged as one of the earliest examples, laying the groundwork for more complex tissue regeneration, while researchers began exploring synthetic materials to create frameworks for tissue growth, which were fundamental in developing scaffold technology[16,6]. The 1980s saw the term "tissue engineering" officially coined, marking the formal recognition of the field as a distinct scientific discipline, with the development of artificial skin for burn victims, combining synthetic and biological materials as one of the first major breakthroughs[17]. During the 1990s, the invention of biodegradable scaffolds provided temporary support for tissue growth, degrading as new tissue formed, and

advances in stem cell research opened new possibilities for tissue engineering by allowing stem cells to differentiate into various tissue types[18]. The 2000s introduced 3D printing technologies, enabling the precise fabrication of complex tissue structures and revolutionizing scaffold design, while progress was made toward engineering functional organs, such as kidneys and hearts, with several promising prototypes being developed[19,1]. From the 2010s to the present, the integration of tissue engineering with regenerative medicine, including gene editing and advanced biomaterials, has pushed the boundaries of what is possible, leading to numerous tissue-engineered products receiving regulatory approval and being used in clinical settings, such as skin, cartilage, and bone grafts[20].

Tissue Scaffolds

Scaffolds are critical components in tissue engineering, acting as the structural framework that supports cell attachment, proliferation, and differentiation by mimicking the extracellular matrix (ECM) of natural tissues[21]. They provide the necessary physical and biochemical environment for tissue formation with primary roles including providing structural support to maintain the shape and integrity of developing tissue, guiding the organization, growth, and differentiation of cells, facilitating the diffusion of nutrients, oxygen, and waste products, and delivering growth factors and other biochemical cues to promote cell activity and tissue formation[22]. Scaffolds can be classified into natural and synthetic types, each with distinct characteristics and applications. Natural scaffolds, derived from biological sources like collagen, gelatin, chitosan, and alginate, are inherently biocompatible, bioactive, and biodegradable, though they may lack mechanical strength, have variability, and face source limitations[23]. Synthetic scaffolds, made from polymers such as polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL), offer tailored properties, reproducibility, and customizability but may cause immune responses and lack inherent bioactivity. Hybrid scaffolds combine natural and synthetic materials, leveraging the strengths of both to enhance mechanical properties, biocompatibility, customizable degradation rates, and functional integration, thereby promoting effective tissue regeneration[24].

Drug-Loaded Microchannels

Drug-loaded microchannels represent an advanced approach in tissue engineering, where micro-scale channels within scaffolds are loaded with therapeutic agents, serving as reservoirs to deliver drugs directly to the engineered tissue in a controlled manner[25]. This integration aims to enhance the therapeutic efficacy and functionality of the tissue construct by ensuring controlled release at specific rates and durations, targeting drug delivery to the site of tissue regeneration to minimize systemic side effects and enhance local efficacy, and carrying multiple drugs or bioactive agents for simultaneous therapies to support tissue regeneration[26]. Incorporating drug delivery systems into scaffolds offers numerous benefits, including enhanced regeneration through localized delivery of growth factors and bioactive molecules that accelerate cell proliferation, differentiation, and tissue maturation, infection prevention through antimicrobial agents, reduced inflammation via localized antiinflammatory drugs, minimized systemic side effects, customized treatment tailored to environmental triggers or predetermined time frames, improved integration through controlled release of angiogenic factors, and multiphase release for immediate therapeutic effects followed by sustained maintenance doses[27]. This combination of structural scaffolds and controlled drug delivery holds great promise for improving tissue regeneration outcomes and expanding clinical applications. The ongoing development of new materials and technologies is expected to further enhance the efficacy and versatility of drug-loaded scaffolds in the future[28].

Biofabrication Techniques

Biofabrication is the process of creating complex biological products, structures, and systems using various techniques that integrate biological and engineering principles[5]. This field lies at the intersection of biology, materials science, engineering, and medicine, aiming to produce constructs that can mimic the structure and function of natural tissues and organs. The ultimate goal of biofabrication is to produce functional tissues and organs for medical applications, including transplantation, disease modeling, and drug testing[29]. The significance of biofabrication is profound, with potential impacts including:

1. Advancement in Medical Treatments

Biofabrication stands at the forefront of personalized medical treatments, offering the potential to create patient-specific tissues and organs[30]. By utilizing a patient's own cells, biofabricated constructs are immunologically compatible, significantly reducing the risk of rejection. This approach can enhance the success rates of organ transplants and tissue repairs, as the bioengineered tissues seamlessly integrate with the patient's body[6,9]. Moreover, these tailored tissues can be designed to address specific anatomical and functional needs, providing more effective treatments compared to traditional methods[12]. For instance, biofabricated skin grafts for burn victims or cartilage for joint repair can be custom-designed to fit the patient perfectly, leading to faster recovery and better functional outcomes. The precision and customization inherent in biofabrication translate into medical interventions that are not only more effective but also safer and more reliable, marking a significant advancement in the field of regenerative medicine[21].

2. Reduction in Organ Shortage

One of the most pressing issues in transplantation medicine is the severe shortage of donor organs. Biofabrication offers a groundbreaking solution to this problem by enabling the creation of bioengineered organs[31]. With advancements in techniques such as 3D bioprinting, it is now possible to fabricate organs that replicate the complex architecture and functionality of natural organs. These bioengineered organs can be produced on demand, potentially providing an unlimited supply and drastically reducing wait times for patients in need of transplants[7,8]. This capability not only addresses the critical shortage but also eliminates the ethical and logistical challenges associated with organ donation. For example, a biofabricated heart or kidney can be created to match a patient's specific biological requirements, thus bypassing the need for finding a compatible donor. The potential to save countless lives by providing timely and suitable organs represents a monumental leap forward in medical science[32].

3. Enhanced Drug Development

Biofabricated tissues play a crucial role in transforming drug development processes. Traditional drug testing methods often rely on animal models or simplistic cell cultures, which may not accurately predict human responses[33]. Biofabricated tissues, however, can mimic the microarchitecture and functionality of human tissues more precisely, offering a more relevant platform for testing pharmaceutical compounds. This allows for highthroughput drug screening, where multiple drugs can be tested simultaneously on bioengineered tissues, accelerating the identification of effective treatments[34]. Additionally, biofabricated tissues enable the creation of disease models that closely replicate the conditions found in human patients[12]. This facilitates a better understanding of disease mechanisms and the development of targeted therapies. By improving the accuracy and efficiency of drug testing,

biofabrication contributes to the development of safer and more effective pharmaceuticals, ultimately enhancing patient outcomes[35].

4. Innovative Research

The field of biofabrication is a catalyst for innovative research in regenerative medicine and tissue engineering. By providing a controlled environment to study complex biological processes, biofabrication techniques allow researchers to delve into the intricacies of tissue development, disease progression, and cellular interactions[36]. For instance, organoids and tissue chips created through biofabrication can replicate the structure and function of human organs on a miniaturized scale, serving as powerful models for studying organ development and disease[37]. These models can reveal insights into how tissues respond to various stimuli, paving the way for new therapeutic approaches. Moreover, the ability to manipulate the microenvironment of biofabricated tissues enables precise experimentation, fostering discoveries that can lead to novel regenerative treatments[22]. The interdisciplinary nature of biofabrication research, bringing together expertise from biology, engineering, and materials science, drives innovation and opens up new frontiers in biomedical science. This collaborative effort not only advances our understanding of fundamental biological processes but also translates into practical applications that improve healthcare outcomes[19].

Various Biofabrication Methods

Biofabrication encompasses a range of methods, each with unique advantages and applications. Key biofabrication methods include:

1. 3D Bioprinting

3D bioprinting is a revolutionary additive manufacturing technique that constructs three-dimensional tissue structures by depositing bioinks layer by layer. These bioinks typically consist of living cells, growth factors, and biomaterials, allowing for the precise fabrication of complex tissue architectures[20]. The process begins with the creation of a digital model of the desired tissue, which is then sliced into thin layers. The bioprinter deposits the bioink layer by layer, following the digital blueprint, to build up the tissue structure[38]. This method allows for exceptional control over the spatial arrangement of cells, enabling the creation of tissues with intricate geometries and heterogeneous compositions[21,6]. 3D bioprinting's versatility makes it suitable for a wide range of applications, including the production of scaffolds that provide structural support for tissue regeneration, the creation of functional tissues for research and therapeutic purposes, and the potential fabrication of entire organs for transplantation[19]. The ability to customize the composition and architecture of bioprinted tissues to match the specific needs of patients marks a significant advancement in personalized medicine[1].

2. Electrospinning

Electrospinning is a versatile technique used to create fibrous scaffolds that closely mimic the extracellular matrix (ECM) of natural tissues. The process involves applying a high-voltage electric field to a polymer solution, causing the formation of a thin polymer jet that solidifies into fibers as it travels through the air and is collected on a grounded substrate[2,4]. The resulting fibrous scaffold exhibits a high surface area-to-volume ratio and significant porosity, which are critical for promoting cell attachment, proliferation, and differentiation. These properties make electrospun scaffolds particularly well-suited for tissue engineering applications[39]. The fibers can be composed of various natural or synthetic polymers, allowing for the customization of the scaffold's mechanical properties and degradation rates to suit specific tissue engineering needs. Electrospinning is widely used to produce scaffolds for

skin, bone, cartilage, and vascular tissue engineering, among others, providing a supportive framework that encourages tissue regeneration and integration with the host tissue[40].

3. Microfluidics

Microfluidics involves the manipulation of small volumes of fluids within microscale channels, offering precise control over the cellular environment. This technology allows researchers to create highly controlled microenvironments that can mimic the conditions found in vivo, making it an invaluable tool for tissue engineering and biomedical research[5]. Microfluidic devices can be used to create tissue constructs by controlling the distribution and organization of cells within the microchannels, facilitating the formation of complex tissue structures. Additionally, microfluidic platforms can be designed as organ-on-chip models that replicate the architecture and function of human organs on a microscale[17,4]. These models are used for studying physiological and pathological processes, as well as for high-throughput drug screening, providing insights into drug efficacy and toxicity in a more human-relevant context. The ability to precisely manipulate the microenvironment within microfluidic devices also enables the study of cell behavior, tissue development, and disease mechanisms under highly controlled conditions[41].

4. Self-Assembly

Self-assembly is a natural process by which cells and biomaterials spontaneously organize into structured arrangements without the need for external guidance. This process leverages the inherent properties of cells and biomolecules to form organized tissues that closely mimic the architecture and function of natural tissues[42]. In tissue engineering, self-assembly can be harnessed to create complex tissue constructs through the careful design of biomaterials and cellular conditions. For example, cells can be encouraged to form aggregates or spheroids, which then fuse to create larger tissue structures[1,9]. Biomaterials can be engineered to provide the appropriate cues for cell self-assembly, promoting the formation of desired tissue architectures. Self-assembly is particularly useful for creating tissues with complex internal organization, such as the layered structures of skin or the branching networks of vascular tissues. By mimicking the natural processes of tissue formation, self-assembly offers a straightforward and efficient approach to tissue engineering, reducing the need for complex fabrication techniques and equipment[43].

5. Decellularization and Recellularization

Decellularization and recellularization are complementary techniques used to create bioengineered organs with native-like structures and mechanical properties. The process begins with decellularization, which involves removing all cellular components from a donor organ or tissue, leaving behind the extracellular matrix (ECM)[44]. This ECM serves as a natural scaffold that retains the original organ's architecture and biochemical composition. Decellularized scaffolds provide an ideal framework for tissue engineering, as they offer the structural and mechanical cues necessary for tissue regeneration[13]. Following decellularization, the scaffold is recellularized by introducing patient-specific cells, which repopulate the ECM and regenerate the tissue[45]. This technique allows for the creation of bioengineered organs that are immunologically compatible with the patient, reducing the risk of rejection. Decellularization and recellularization have been used to produce a variety of tissues and organs, including heart valves, blood vessels, and whole organs such as lungs and kidneys. By leveraging the natural properties of the ECM and patient-specific cells, this

approach holds great promise for advancing regenerative medicine and addressing the shortage of donor organs[46].

4. 3D Bioprinting Techniques and Materials Used

3D bioprinting is a cutting-edge biofabrication technique that constructs three-dimensional tissue structures through a layer-by-layer deposition process[23]. Several techniques and materials are used in 3D bioprinting:




Figure 1 Schematic illustration of the 3D-printed scaffold manufacturing for bone tissue regeneration **Techniques:**

1. Inkjet Bioprinting:

Inkjet bioprinting utilizes thermal or piezoelectric forces to eject droplets of bioink onto a substrate. This method is advantageous due to its high speed and resolution, making it suitable for printing cells and biomolecules with precision[47]. However, inkjet bioprinting has limitations, including the potential for thermal stress on cells and a limited range of bioink viscosities that can be used effectively. These factors can influence the viability and functionality of the printed cells, thus impacting the overall effectiveness of the bioprinting process[14].

2. Extrusion Bioprinting:

Extrusion bioprinting involves the continuous extrusion of bioink through a nozzle to form filaments. This method enables the construction of complex, three-dimensional structures by steadily depositing bioink layer by layer[48]. The bioink, a mixture of cells and biomaterials, is pushed through the nozzle, creating continuous strands that can be precisely positioned to build tissue-like constructs[4]. One of the primary advantages of extrusion bioprinting is its ability to handle high-viscosity materials. This capability allows for the use of bioinks with a wide range of compositions, including those with high cell densities, which are essential for creating biologically relevant structures[2]. The method's robustness makes it suitable for printing large and intricate tissue constructs, providing a versatile platform for various biomedical applications[49].

3. Laser-Assisted Bioprinting (LAB):

Laser-Assisted Bioprinting (LAB) uses a focused laser beam to transfer bioink from a donor substrate to a receiver substrate. This innovative method involves directing the laser beam to a thin layer of bioink on the donor substrate, which generates a high-pressure bubble that propels the bioink droplets onto the receiver substrate[13]. This precise technique allows for the meticulous placement of cells and biomaterials, facilitating the construction of intricate and finely detailed biological structures. The advantages of LAB are notable, particularly in terms of its high resolution and precise cell placement[50]. The focused laser beam can target specific locations with great accuracy, ensuring that cells and biomaterials are deposited exactly where needed. This precision minimizes the risk of cell damage and ensures that the structural and functional properties of the printed tissues are maintained[33]. Additionally, the method exerts minimal shear stress on the cells, preserving their viability and promoting healthy cell function throughout the bioprinting process[51].

Materials:

Bioinks: Composed of cells, biomaterials, and bioactive molecules. Common biomaterials include:

- **Natural Polymers:** Collagen, gelatin, alginate, and fibrin. These materials are biocompatible and mimic the natural extracellular matrix.
- **Synthetic Polymers:** Polyethylene glycol (PEG), polylactic acid (PLA), and polycaprolactone (PCL). These materials offer tunable mechanical properties and degradation rates.
- **Hybrid Materials:** Combining natural and synthetic polymers to leverage the advantages of both[52].

Electrospinning

Electrospinning is a versatile technique for producing fibrous scaffolds that mimic the extracellular matrix (ECM) of natural tissues. The process involves applying a high-voltage electric field to a polymer solution or melt, which causes the ejection of a thin jet of the polymer. As the jet travels through the air, it solidifies and forms continuous fibers that are collected on a grounded substrate[53]. The process begins with the preparation of a polymer solution, where the polymer is dissolved in a suitable solvent to create a solution with appropriate viscosity and conductivity. A high voltage (typically 10-30 kV) is then applied between the polymer solution (held in a syringe) and a collector, inducing a charge on the surface of the polymer solution that causes it to overcome surface tension and form a jet[12,6]. As the jet travels towards the collector, the solvent evaporates, and the polymer solidifies into thin fibers that are collected on a grounded substrate, forming a non-woven fibrous mat. Materials used in electrospinning include natural polymers like collagen, gelatin, chitosan, silk fibroin, and hyaluronic acid, which are biocompatible and bioactive, promoting cell attachment and growth[54,9]. Synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polyethylene oxide (PEO), and polyurethane offer tunable mechanical properties and controlled degradation rates. Composite materials, blending natural and synthetic polymers, create hybrid scaffolds that combine the biocompatibility of natural polymers with the mechanical strength of synthetic polymers[55]. Electrospinning offers several benefits for scaffold production: high surface area due to the nanoscale diameter of fibers, high porosity and interconnected pores facilitating cell infiltration and vascularization, mimicry of the natural ECM providing a conducive environment for cell growth and differentiation, versatility in using a wide range of polymers allowing customization of scaffold

properties, and scalability for large-scale production suitable for commercial applications[13,8].

Drug Loading and Release Mechanisms

Drug loading and release mechanisms are crucial aspects of drug delivery systems, especially in the context of biomedical applications such as tissue engineering and controlled drug release. These mechanisms govern how drugs are incorporated into carriers (like scaffolds or nanoparticles) and subsequently released in a controlled manner to achieve therapeutic effects[56].

Table 1: Parameters that should be considered for each drug-loading method.

Method	Parameters	Considerations	References
Physical Adsorption	Surface area of scaffold, drug concentration	- Surface Area: Higher surface area allows for greater drug adsorption	[3]
Covalent Bonding	Functional groups, coupling chemistry	Drug Concentration: Determines loading capacity and release kinetics.	[5]
Encapsulation	Encapsulation efficiency, particle size	- Functional Groups: Availability on scaffold and drug for effective bonding.	[8]
Diffusion-Based Systems	Diffusion coefficient, scaffold porosity	- Coupling Chemistry: Reaction conditions and specificity of bonding.	[1]
Degradation-Based Systems	Polymer degradation rate, drug-polymer interactions	- Encapsulation Efficiency: Determines amount of drug loaded per unit volume.	[13]
StimuliResponsive Systems	Trigger mechanism (e.g., pH, temperature), responsiveness time	- Particle Size: Affects release rate and cellular uptake.	[21]

Methods of Drug Loading Physical Adsorption

Physical adsorption involves the non-covalent attachment of drug molecules onto the surface of a carrier material. This method is relatively simple and does not alter the chemical structure of the drug[57]. It relies on physical interactions such as van der Waals forces, hydrogen bonding, or electrostatic interactions between the drug and the carrier material. Physical adsorption is advantageous due to its ease of implementation and versatility across different types of drugs and carrier materials[12].

Covalent Bonding

Covalent bonding entails the formation of stable chemical bonds between drug molecules and the carrier material[22]. This method usually involves modifying the drug molecule to introduce functional groups that can react with specific functional groups on the carrier material. Covalent bonding provides a more stable attachment compared to physical adsorption and can offer controlled release properties by regulating the bond strength or cleavage mechanisms[58].

Encapsulation

Encapsulation involves entrapping drug molecules within the carrier material, typically in the form of nanoparticles, microspheres, or liposomes. The drug is either physically trapped within the carrier matrix or encapsulated in a vesicle structure[24]. Encapsulation protects the drug from degradation and facilitates controlled release through diffusion or degradation of the carrier material. This method is advantageous for delivering hydrophobic drugs and can improve drug stability and bioavailability[29].

Controlled Release Systems Diffusion-Based Systems

Diffusion-based systems rely on the passive diffusion of drug molecules through a carrier matrix. The release rate is governed by the concentration gradient between the carrier and the surrounding medium[30]. Factors such as the size of the carrier matrix pores, drug solubility, and carrier composition influence the diffusion rate. Diffusion-based systems are simple to design but may exhibit burst release effects initially, followed by a sustained release phase[31].

Degradation-Based Systems

Degradation-based systems involve carriers that degrade over time, releasing encapsulated or adsorbed drug molecules. The degradation can be triggered by environmental factors such as pH, enzymes, or temperature[12]. This method allows for precise control over the release kinetics by adjusting the degradation rate of the carrier material. Degradation-based systems are particularly useful for achieving sustained release profiles and minimizing systemic toxicity[59].

Stimuli-Responsive Systems

Stimuli-responsive systems release drugs in response to specific external stimuli, such as light, temperature, pH changes, or magnetic fields[13]. These systems can be designed using smart materials that undergo conformational changes or disassembly in response to the stimulus, thereby releasing the drug payload. Stimuli-responsive systems offer precise spatiotemporal control over drug release and are being explored for targeted drug delivery applications and personalized medicine[60].




Figure 2: Overall scheme of the heparin encapsulated fiber-based scaffold for inhibiting thrombosis with enhanced vascular regeneration.

Bone and Cartilage Regeneration Specific Scaffolds and Drug Delivery Systems Used

Bone and cartilage regeneration aim to repair defects caused by trauma, disease, or degeneration using biomaterial scaffolds and targeted drug delivery systems[33]. For bone regeneration, scaffolds often utilize materials like hydroxyapatite (HA), calcium phosphates, or biodegradable polymers such as polylactic acid (PLA) or poly(lactic-co-glycolic acid) (PLGA)[61]. These materials provide structural support and mimic the composition of natural bone tissue. Drug delivery systems integrated into these scaffolds may include growth factors like bone morphogenetic proteins (BMPs), which stimulate osteogenesis, or antibiotics to prevent infection[44]. In cartilage regeneration, scaffolds are designed to mimic the extracellular matrix (ECM) of cartilage, offering mechanical support and promoting chondrogenic differentiation. Common scaffold materials include hyaluronic acid (HA), collagen, and synthetic polymers like polycaprolactone (PCL) or polyethylene glycol (PEG). Drug-loaded scaffolds may deliver growth factors such as transforming growth factor-beta (TGF- β) or insulin-like growth factor (IGF), which enhance chondrocyte proliferation and matrix synthesis[62].

Vascular and Cardiac Tissue Engineering Innovations in Scaffold Designs for Vascular and Cardiac Tissues

Vascular and cardiac tissue engineering aims to repair or replace damaged blood vessels and myocardium using biomaterial scaffolds and cell-based therapies[2]. In **vascular tissue engineering**, scaffolds are designed to mimic the ECM of blood vessels and promote endothelialization for vascular regeneration. Materials such as decellularized matrices, synthetic polymers (e.g., polyethylene glycol), or natural polymers (e.g., collagen, fibrin) are used to create scaffolds that support cell adhesion, proliferation, and vascular network formation[22]. Controlled release systems deliver angiogenic factors like vascular endothelial growth factor (VEGF) to enhance vascularization and graft integration. For **cardiac tissue engineering**, scaffolds are tailored to mimic the mechanical properties and electrical conductivity of cardiac tissue[42]. Biomaterials like decellularized heart tissue, hydrogels, or conductive polymers are used to create scaffolds that support cardiomyocyte attachment and function. Drug-loaded scaffolds may deliver factors like growth factors or anti-inflammatory agents to promote tissue repair and regeneration post-myocardial infarction[19].

Neural Tissue Engineering Advances in Scaffolds for Neural Regeneration

Neural tissue engineering focuses on repairing or replacing damaged nervous tissue using biomaterial scaffolds and neurotrophic factors[1]. Scaffolds for **neural regeneration** are designed to provide physical support, promote axonal guidance, and enhance neuronal differentiation. Materials such as biocompatible polymers (e.g., poly(lactic-co-glycolic acid), polycaprolactone), hydrogels (e.g., agarose, alginate), or conductive materials (e.g., carbon nanotubes, graphene) are used to create scaffolds with tailored mechanical properties and electrical conductivity[39]. Drug-loaded scaffolds may deliver neurotrophic factors (e.g., nerve growth factor, brain-derived neurotrophic factor) to support neuronal survival and axonal outgrowth. Successes in neural tissue engineering include the development of scaffolds that support functional recovery in spinal cord injuries, peripheral nerve injuries, and neurodegenerative diseases[40]. For example, scaffold-based delivery of growth factors has shown promise in promoting axonal regeneration and functional neural connectivity in

preclinical models. Challenges include achieving precise control over scaffold architecture to guide neurite outgrowth, optimizing biocompatibility to prevent inflammatory responses, and integrating scaffolds with existing neural networks for functional recovery[63].

Future Trends

Future trends in regenerative medicine are being shaped by advances in technology and materials science, paving the way for novel therapeutic approaches and breakthroughs in tissue engineering. Emerging technologies such as bioprinting, organ-on-a-chip models, and gene editing (e.g., CRISPR/Cas9) offer new avenues for precise control over tissue architecture and functionality, enabling the fabrication of patient-specific tissues and organs with enhanced physiological relevance and therapeutic efficacy[64]. Innovations in biomaterials, including bioactive ceramics, biodegradable polymers, and smart materials (e.g., stimuli-responsive hydrogels), are enabling the development of scaffolds with tailored mechanical, biological, and degradation properties. Functionalized materials that mimic the dynamic and hierarchical structure of native tissues are poised to revolutionize tissue regeneration and organ repair[65]. Future research directions focus on interdisciplinary collaborations, translational research, and addressing remaining challenges to accelerate clinical translation and patient benefits. Interdisciplinary collaboration between researchers, clinicians, engineers, and industry stakeholders is crucial for integrating expertise in biomaterials science, cell biology, immunology, and clinical medicine, facilitating the development of comprehensive solutions to complex biomedical challenges[66]. Translational research emphasizes bridging the gap between benchtop research and bedside implementation, with efforts including preclinical validation, clinical trials, and outcome assessments to demonstrate the safety, efficacy, and therapeutic potential of regenerative medicine therapies[67]. Potential breakthroughs include achieving organ regeneration through tissue engineering, personalized medicine approaches based on patient-specific biomaterials and therapies, and advancing regenerative strategies for currently untreatable conditions such as neurodegenerative diseases and complex organ failures[69]. Addressing technical, biological, regulatory, and commercialization challenges while embracing emerging technologies and materials will drive the future of regenerative medicine, fostering interdisciplinary collaboration, advancing translational research, and pursuing groundbreaking innovations to transform patient care and improve quality of life worldwide[70].

Conclusion

Throughout this exploration of biofabricated tissue scaffolds in regenerative medicine, several key points have emerged regarding their significance, potential, and current challenges. Biofabricated scaffolds play a crucial role in tissue engineering by providing structural support and creating an environment conducive to cell adhesion, proliferation, and differentiation. They are designed to mimic the complex architecture and functionalities of native tissues, utilizing materials such as biodegradable polymers, natural ECM components, and advanced synthetic biomaterials. These scaffolds hold immense potential across diverse applications, from repairing bone and cartilage to enhancing skin wound healing and engineering complex tissues like blood vessels and nerves. Despite these advancements, challenges persist in optimizing fabrication techniques for scalability and reproducibility, ensuring long-term biocompatibility and integration with host tissues, navigating regulatory pathways for clinical translation, and addressing economic considerations for widespread adoption in healthcare. Addressing these challenges requires continued research, interdisciplinary collaboration, and innovation to maximize the clinical impact of biofabricated scaffold technologies. Looking forward, the

future of biofabricated tissue scaffolds in regenerative medicine promises significant advancements and transformative possibilities. Technological innovations, such as 3D bioprinting and microfluidics, are poised to revolutionize scaffold fabrication by enabling precise control over architecture, mechanical properties, and bioactive molecule distribution. Future research directions will expand applications into complex organ regeneration, such as liver, kidney, and pancreatic tissues, leveraging novel biomaterials and growth factors tailored to specific tissue needs. Integrating bioinformatics and computational modeling will enhance scaffold design and treatment optimization, paving the way for personalized regenerative therapies.

References

- [1] S.K.L. Levengood and M. Zhang, "Chitosan-Based Scaffolds for Bone Tissue Engineering," *J. Mater. Chem. B*, vol. 2, pp. 3161-3184, 2014. doi: 10.1039/c4tb00027g.
- [2] R.C. Gupta, R. Lall, A. Srivastava, and A. Sinha, "Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory," *Front. Vet. Sci.*, vol. 6, p. 192, 2019. doi: 10.3389/fvets.2019.00192.
- [3] E. Rosellini and M.G. Cascone, "Microfluidic Fabrication of Natural Polymer-Based Scaffolds for Tissue Engineering Applications: A Review," *Biomimetics*, vol. 8, p. 74, 2023. doi: 10.3390/biomimetics8010074.
- [4] F. Abasalizadeh, S.V. Moghaddam, E. Alizadeh, E. Akbari, E. Kashani, S.M.B. Fazljou, M. Torbati, and A. Akbarzadeh, "Alginate-Based Hydrogels as Drug Delivery Vehicles in Cancer Treatment and Their Applications in Wound Dressing and 3D Bioprinting," *J. Biol. Eng.*, vol. 14, p. 8, 2020. doi: 10.1186/s13036-020-0227-7. [5] J. Sun and H. Tan, "Alginate-Based Biomaterials for Regenerative Medicine Applications," *Materials*, vol. 6, pp. 1285-1309, 2013. doi: 10.3390/ma6041285.
- [6] H.H. Tønnesen and J. Karlsen, "Alginate in Drug Delivery Systems," *Drug Dev. Ind. Pharm.*, vol. 28, pp. 621-630, 2002. doi: 10.1081/DDC-120003853.
- [7] L.N. Novikova, A. Mosahebi, M. Wiberg, G. Terenghi, J.-O. Kellerth, and L.N. Novikov, "Alginate Hydrogel and Matrigel as Potential Cell Carriers for Neurotransplantation," *J. Biomed. Mater. Res. Part A*, vol. 77, pp. 242-252, 2006. doi: 10.1002/jbm.a.30603.
- [8] L. Pérez-Álvarez, L. Ruiz-Rubio, and J.L. Vilas-Vilela, "Determining the Deacetylation Degree of Chitosan: Opportunities To Learn Instrumental Techniques," *J. Chem. Educ.*, vol. 95, pp. 1022-1028, 2018. doi: 10.1021/acs.jchemed.7b00902.
- [9] M.M. Al-Rooqi, M.M. Hassan, Z. Moussa, R.J. Obaid, N.H. Suman, M.H. Wagner, S.S.A. Natto, and S.A. Ahmed, "Advancement of Chitin and Chitosan as Promising Biomaterials," *J. Saudi Chem. Soc.*, vol. 26, p. 101561, 2022. doi: 10.1016/j.jscs.2022.101561.
- [10] P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," *Pharmaceutics*, vol. 15, no. 8, p. 2066, 2023.

- [11] P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," *Pharma Science Monitor*, vol. 9, no. 2, 2018.
- [12] P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," *Int J Pharm Investig*, vol. 11, no. 1, pp. 69–75, 2021.
- [13] P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," *The Chinese Journal of Artificial Intelligence*, 2023.
- [14] P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in *Blockchain for Healthcare Systems*, 2021, pp. 97–113.
- [15] P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium—A Review," *World J. Pharm. Pharm. Sci*, vol. 7, no. 9, pp. 271-287, 2018.
- [16] D. Puppi, et al., "Additive manufacturing of wet-spun polymeric scaffolds for bone tissue engineering," *Biomed. Microdevices*, vol. 14, pp. 1115-1127, 2012, doi: 10.1007/s10544-012-9677-0.
- [17] L. Kong and G.R. Ziegler, "Fabrication of kappa-carrageenan fibers by wet spinning: spinning parameters," *Materials*, vol. 4, pp. 1805-1817, 2011, doi: 10.3390/ma4101805.
- [18] I.B. Leonor, M.T. Rodrigues, M.E. Gomes, and R.L. Reis, "In situ functionalization of wet-spun fibre meshes for bone tissue engineering," *J. Tissue Eng. Regen. Med.*, vol. 5, pp. 104-111, 2011.
- [19] K. Tuzlakoglu, C.M. Alves, J.F. Mano, and R.L. Reis, "Production and characterization of chitosan fibers and 3-D fiber mesh scaffolds for tissue engineering applications," *Macromol. Biosci.*, vol. 4, pp. 811-819, 2004.
- [20] D. Puppi, et al., "Development of 3D wet-spun polymeric scaffolds loaded with antimicrobial agents for bone engineering," *J. Bioact. Compat. Polym.*, vol. 26, pp. 478-492, 2011, doi: 10.1177/0883911511415918.
- [21] M. Nouri, M. Abbasi, M. Seraj, and L. Mehraz, "Fabrication and characterization of drug-loaded wet spun polycaprolactone fibers," *J. Text. Inst.*, vol. 112, pp. 462-469, 2021, doi: 10.1080/00405000.2020.1764773.
- [22] J. Pruiell and J. White, "Structure development during polymer processing: studies of the melt spinning of polyethylene and polypropylene fibres," *Polym. Eng. Sci.*, vol. 15, pp. 660-667, 1975.
- [23] S.P. Rwei, Z.F. Jue, and F.L. Chen, "PBT/PET conjugated fibers: melt spinning, fiber properties, and thermal bonding," *Polym. Eng. Sci.*, vol. 44, pp. 331344, 2004.
- [24] X. Zhang, et al., "Polypropylene/montmorillonite composites and their application in hybrid fiber preparation by melt-spinning," *J. Appl. Polym. Sci.*, vol. 92, pp. 552-558, 2004.
- [25] A.R. Bhattacharyya, et al., "Crystallization and orientation studies in polypropylene/single wall carbon nanotube composite," *Polymer*, vol. 44, pp. 23732377, 2003, doi: 10.1016/s0032-3861(03)00073-9.

- [26] A.V. Do, B. Khorsand, S.M. Geary, and A.K. Salem, "3D printing of scaffolds for tissue regeneration applications," *Adv. Healthc. Mater.*, vol. 4, pp. 1742-1762, 2015, doi: 10.1002/adhm.201500168.
- [27] X. Wei, C. Liu, Z. Wang, and Y. Luo, "3D printed core-shell hydrogel fiber scaffolds with NIR-triggered drug release for localized therapy of breast cancer," *Int. J. Pharm.*, vol. 580, article 119219, 2020, doi: 10.1016/j.ijpharm.2020.119219.
- [28] C. Fu, Z. Shao, and V. Fritz, "Animal silks: their structures, properties and artificial production," *Chem. Commun.*, pp. 6515-6529, 2009.
- [29] S. Lin, et al., "Predictive modelling-based design and experiments for synthesis and spinning of bioinspired silk fibres," *Nat. Commun.*, vol. 6, pp. 1-12, 2015.
- [30] J. Yan, G. Zhou, D.P. Knight, Z. Shao, and X. Chen, "Wet-spinning of regenerated silk fiber from aqueous silk fibroin solution: discussion of spinning parameters," *Biomacromolecules*, vol. 11, pp. 1-5, 2010.
- [31] C.S. Miranda, et al., "Tunable spun fiber constructs in biomedicine: influence of processing parameters in the fibers' architecture," *Pharmaceutics*, vol. 14, article 10.3390/pharmaceutics14010164, 2022.
- [32] J. Wang, et al., "Encapsulation of monodisperse microdroplets in nanofibers through a microfluidic-electrospinning hybrid method," *Langmuir*, vol. 39, pp. 813819, 2023, doi: 10.1021/acs.langmuir.2c02808.
- [33] L. Keßler, Z. Mirzaei, J.C. Kade, and R. Luxenhofer, "Highly porous and drug-loaded amorphous solid dispersion microfiber scaffolds of indomethacin prepared by melt electrowriting," *ACS Appl. Poly. Mater.*, vol. 5, pp. 913-922, 2023, doi: 10.1021/acsapm.2c01845.
- [34] X. Ding, Y. Yu, L. Shang, and Y. Zhao, "Histidine-triggered GO hybrid hydrogels for microfluidic 3D printing," *ACS Nano*, 2022, doi: 10.1021/acsnano.2c09850.
- [35] Z. Zhao, A. Ukidve, J. Kim, and S. Mitragotri, "Targeting strategies for tissuespecific drug delivery," *Cell*, vol. 181, pp. 151-167, 2020.
- [36] W. Samprasit, et al., "Mucoadhesive electrospun chitosan-based nanofibre mats for dental caries prevention," *Carbohydr. Polym.*, vol. 117, pp. 933-940, 2015.
- [37] K. Semjonov, et al., "Melt-electrospinning as a method to improve the dissolution and physical stability of a poorly water-soluble drug," *Eur. J. Pharm. Sci.*, vol. 121, pp. 260-268, 2018, doi: 10.1016/j.ejps.2018.06.004.
- [38] I.-C. Liao, A.C. Wan, E.K. Yim, and K.W. Leong, "Controlled release from fibers of polyelectrolyte complexes," *J. Control. Release*, vol. 104, pp. 347-358, 2005.
- [39] S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in *2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI)*. IEEE, 2022.
- [40] V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," *International Journal of Pharmaceutical Sciences and Research*, vol. 11, no. 5, pp. 2193-2198, 2020.
- [41] A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," *GSC biol pharm sci*, vol. 19, no. 3, pp. 148-155, 2022.

- [42] B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., *Encyclopedia of green materials*. Singapore: Springer Nature Singapore, 2022.
- [43] P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," *Am J PharmTech Res*, vol. 9, no. 3, pp. 321–331, 2019.
- [44] P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in *The Flavonoids*, 2024, pp. 131-152.
- [45] P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (*Echinochloa esculenta*) starch," *ACS Omega*, vol. 8, no. 33, pp. 30294–305, 2023.
- [46] C. Goyal et al., "Estimation of shelf-life of Balachaturbhadraka syrup containing different sweetening agents," *Res J Pharm Technol*, pp. 5078–5083, 2022.
- [47] T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," *J Pharm Res Int*, pp. 70–78, 2021.
- [48] M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," *Phytomed Plus*, vol. 3, no. 2, p. 100445, 2023.
- [49] A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," *J Chem Pharm Sci*, vol. 12, no. 03, pp. 71–78, 2019.
- [50] M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," *Nat Prod J*, 2022.
- [51] M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," *ACS Omega*, vol. 7, no. 40, pp. 35506–35514, 2022.
- [52] M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," *ACS Omega*, vol. 8, no. 13, pp. 11750–11767, 2023.
- [53] Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," *J Pharm Res Int*, pp. 54–63, 2021.
- [54] Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," *J Pharm Res Int*, pp. 21–29, 2021.
- [55] V. Raghuvanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," *Journal of Pharmaceutical Negative Results*, pp. 1811-1820, 2022.
- [56] K. K. Sahu et al., "Utility of nanomaterials in wound management," in *Nanotechnological Aspects for Next-Generation Wound Management*, 2024, pp. 101–130.
- [57] S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," *J Infect Public Health*, vol. 15, no. 5, pp. 566–572, 2022.
- [58] S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," *J Pharm Res Int*, pp. 5–13, 2021.
- [59] S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," *Journal of Pharmaceutical Research International*, vol. 32, no. 36, pp. 82-88, 2022.

- [60] S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," *WJPMR*, vol. 8, no. 4, pp. 216–225, 2022.
- [61] S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in *Advances in Flavonoids for Human Health and Prevention of Diseases*, 2024, pp. 23-46.
- [62] S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in *Blockchain for Healthcare Systems*, 2021, pp. 61–79.
- [63] S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," *Journal of Pharmaceutical Negative Results*, pp. 1463-1469, 2022.
- [64] R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in *2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART)*, 2023, pp. 556-561.
- [65] P. Bhatt et al., "Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (*Echinochloa frumentacea*) Grains Starch," *Stärke/Starch*, May 2024, doi: <https://doi.org/10.1002/star.202300285>.
- [66] V. Kumar et al., "Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study," *Journal of bioactive and compatible polymers*, May 2024, doi: <https://doi.org/10.1177/08839115241249143>.
- [67] M.M. Islam, M. Shahruzzaman, S. Biswas, M. Nurus Sakib, and T.U. Rashid, "Chitosan Based Bioactive Materials in Tissue Engineering Applications—A Review," *Bioact. Mater.*, vol. 5, pp. 164-183, 2020. doi: 10.1016/j.bioactmat.2020.01.012.
- [68] S.B. Qasim, M.S. Zafar, S. Najeeb, Z. Khurshid, A.H. Shah, S. Husain, and I.U. Rehman, "Electrospinning of Chitosan-Based Solutions for Tissue Engineering and Regenerative Medicine," *Int. J. Mol. Sci.*, vol. 19, p. 407, 2018. doi: 10.3390/ijms19020407.
- [69] C. Ji, N. Annabi, A. Khademhosseini, and F. Dehghani, "Fabrication of Porous Chitosan Scaffolds for Soft Tissue Engineering Using Dense Gas CO₂," *Acta Biomater.*, vol. 7, pp. 1653-1664, 2011. doi: 10.1016/j.actbio.2010.11.043.
- [70] S.G. Lim, S.E. Seo, S.J. Park, J. Kim, Y. Kim, K.H. Kim, J.E. An, and O.S. Kwon, "Real-Time Monitoring of Serotonin with Highly Selective AptamerFunctionalized Conducting Polymer Nanohybrids," *Nano Converg.*, vol. 9, p. 31, 2022. doi: 10.1186/s40580-022-00325-7.